Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology



Status:Archived
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2009
End Date:April 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology


To determine the sensitivity and specificity of the visual assessment of regional tracer
uptake in the Florbetaben PET images compared to histological verification of the presence
or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as
the standard of truth



We found this trial at
6
sites
Clinical Trial Facility
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Trial Facility
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial Facility
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Clinical Trial Facility
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Clinical Trial Facility
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Clinical Trial Facility
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials